Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has recently enjoyed extremely important positive changes in investment behavior: positive upside/downside volume developed, and the stock’s recent price rise disrupted its longer term downtrend.
Significant positive changes in fundamentals have recently occurred for Acadia Pharmaceuticals Inc (NASDAQ: ACAD): the consensus estimate for December, 2024 increased significantly, and significant quarterly sales acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of D. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, ACAD is expected to be a major Value Builder.
Acadia Pharmaceuticals has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Acadia Pharmaceuticals has a very low Appreciation Score of 6 but a good Power Rating of 80, resulting in the Negative Value Trend Rating.
Recent Price Action
On 1/3/24, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock declined by -4.2%, closing at $29.57. NORMAL trading volume accompanied the decline. Relative to the market the stock has been strong over the last nine months but has declined -5.8% during the last week.
Be the first to comment